Given that the design and endpoints of clinical validation studies is priceless information for developers of similar devices (i.e., competitors) applying for FDA clearance via the 510(k) pathway, it would not surprise me at all if this information was purposefully kept secret no matter how flattering it is. Especially for relatively new technology like AI